Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DC-006 Vaccine in Recurrent Ovarian Cancer
NCT01334047Phase 2Terminated
- Start
- Apr 2011
- Primary completion
- Aug 2013
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of DC-006 in epithelial ovarian cancer (EOC). Primary endpoint: Frequency and severity of adverse events up to 3 years. Started Apr 2011; status: terminated.
02
Drugs
DC-006
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on NCT01334047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01334047.